KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Gross Profit (2021 - 2025)

Recursion Pharmaceuticals' Gross Profit history spans 5 years, with the latest figure at $21.3 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 357.8% year-over-year to $21.3 million; the TTM value through Dec 2025 reached $3.7 million, down 72.58%, while the annual FY2025 figure was $3.7 million, 72.59% down from the prior year.
  • Gross Profit reached $21.3 million in Q4 2025 per RXRX's latest filing, up from -$9.5 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $21.3 million in Q4 2025 to a low of -$9.5 million in Q3 2025.
  • Average Gross Profit over 5 years is $1.1 million, with a median of $1.3 million recorded in 2023.
  • The largest YoY upside for Gross Profit was 4170.64% in 2024 against a maximum downside of 916.63% in 2024.
  • A 5-year view of Gross Profit shows it stood at $2.5 million in 2021, then grew by 11.96% to $2.8 million in 2022, then crashed by 64.39% to $1.0 million in 2023, then plummeted by 916.63% to -$8.2 million in 2024, then soared by 357.8% to $21.3 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Gross Profit are $21.3 million (Q4 2025), -$9.5 million (Q3 2025), and -$938000.0 (Q2 2025).